LENZ Therapeutics, Inc. (LENZ)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China market, LENZ said.
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ Therapeutics NASDAQ: LENZ reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption and routine prescribing by eye care professionals are developing more gradually than expected.
LENZ Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 2 | $58.6 | $9.68 | -$48.92 | -83.48% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 13,909 | $272,272.03 | $68,084.55 | -$204,187.48 | -74.99% |
 Joseph Castro Nuveen LLC | 40,190 | $1.86M | $192,912 | -$1.67M | -89.64% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 11 | $100.65 | $54.05 | -$46.6 | -46.3% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 164 | $944.64 | $809.34 | -$135.3 | -14.32% |
LENZ Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Yigal Nochomovitz Citigroup | 893.58 | $5,551.53 | $4,360.65 | -$1,190.88 | -21.45% |
LENZ Therapeutics, Inc. (LENZ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has LENZ Therapeutics, Inc. ever had a stock split?
LENZ Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Evert Schimmelpennink CEO | NASDAQ (NGS) Exchange | 52635N103 CUSIP |
| US Country | 152 Employees | - Last Dividend | 22 Mar 2024 Last Split | - IPO Date |
Overview
LENZ Therapeutics, Inc. is a biopharmaceutical entity committed to innovating and bringing to market treatments that enhance vision for patients across the United States. As a company, LENZ Therapeutics is at the forefront of developing pharmacological solutions aimed at addressing various eye conditions, with a significant focus on presbyopia – a common age-related vision issue. With its headquarters nestled in Del Mar, California, the company leverages its strategic location to tap into the bustling biotechnology scene, propelling its research and development efforts to new heights.
Products and Services
- LNZ100
LNZ100 represents one of LENZ Therapeutics, Inc.'s flagship product candidates, currently in Phase III clinical trials. This potential pharmacological solution is designed to tackle the challenges of presbyopia, aiming to restore clarity and focus to those experiencing age-related changes in their vision. By advancing LNZ100 through the stringent Phase III trial phase, LENZ Therapeutics demonstrates its commitment to scientific innovation and patient care.
- LNZ101
Alongside LNZ100, LNZ101 stands as another pivotal product candidate within LENZ Therapeutics, Inc.'s pipeline, also in Phase III clinical trials for the treatment of presbyopia. LNZ101 is aimed at improving vision for those suffering from this age-related vision deterioration, underscoring the company's focused approach in addressing presbyopia through a diverse portfolio of potential treatments. Each product candidate, including LNZ101, is a testament to LENZ Therapeutics' dedication to advancing ocular health and improving the quality of life for patients.
